{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:56Z","timestamp":1787020796947,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Puma Biotechnology Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13058-019-1112-5","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T06:24:06Z","timestamp":1551248646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-1934","authenticated-orcid":false,"given":"Joanne","family":"Mortimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Jahanzeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/annonc\/mdw695","volume":"28","author":"SM Swain","year":"2017","unstructured":"Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017;28:761\u20138.","journal-title":"Ann Oncol"},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Minckwitz von","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122\u201331.","journal-title":"N Engl J Med"},{"key":"1112_CR3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812\u201323.","journal-title":"J Clin Oncol"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733\u201343.","journal-title":"N Engl J Med"},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","volume":"15","author":"J Andreyev","year":"2014","unstructured":"Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15:e447\u201360.","journal-title":"Lancet Oncol"},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2004.11.015","volume":"227","author":"SK Rabindran","year":"2005","unstructured":"Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005;227:9\u201323.","journal-title":"Cancer Lett"},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-08-1978","volume":"15","author":"KK Wong","year":"2009","unstructured":"Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15:2552\u20138.","journal-title":"Clin Cancer Res"},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301\u20137.","journal-title":"J Clin Oncol"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1016\/j.ejca.2013.07.142","volume":"49","author":"M Martin","year":"2013","unstructured":"Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49:3763\u201372.","journal-title":"Eur J Cancer"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189\u201394.","journal-title":"Nature"},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","volume":"2","author":"A Awada","year":"2016","unstructured":"Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2:1557\u201364.","journal-title":"JAMA Oncol"},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367\u201377.","journal-title":"Lancet Oncol"},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2017;18:1688\u2013700.","journal-title":"Lancet Oncol"},{"key":"1112_CR14","first-page":"13","volume":"11","author":"F Ustaris","year":"2015","unstructured":"Ustaris F, Saura C, Di Palma J, Bryce R, Moran S, Neuman L, et al. Effective management and prevention of neratinib-induced diarrhea. Am J Hematol Oncol. 2015;11:13\u201322.","journal-title":"Am J Hematol Oncol"},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974\u201386.","journal-title":"J Clin Oncol"},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","volume":"57","author":"DT Eton","year":"2004","unstructured":"Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57:898\u2013910.","journal-title":"J Clin Epidemiol"},{"key":"1112_CR17","doi-asserted-by":"crossref","unstructured":"Hurwitz S, Chan A, Iannotti N, Ibrahim E, Chien J, Chan N, et al. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: the CONTROL trial. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2018;78(4 Suppl):Abstract nr P3-14-01.","DOI":"10.1158\/1538-7445.SABCS17-P3-14-01"},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jpainsymman.2007.10.007","volume":"36","author":"NI Cherny","year":"2008","unstructured":"Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manag. 2008;36:413\u201323.","journal-title":"J Pain Symptom Manag"},{"key":"1112_CR19","doi-asserted-by":"publisher","unstructured":"Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, et al. Effects of neratinib on health-related quality-of-life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol. 2019. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdz016\n                    \n                  . [Epub ahead of print]","DOI":"10.1093\/annonc\/mdz016"},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","volume":"112","author":"JP Crown","year":"2008","unstructured":"Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008;112:317\u201325 Erratum in: Breast Cancer Res Treat 2009;113:409\u2013410.","journal-title":"Breast Cancer Res Treat"},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1634\/theoncologist.5-3-250","volume":"5","author":"RB Arbuckle","year":"2000","unstructured":"Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist. 2000;5:250\u20139.","journal-title":"Oncologist"},{"key":"1112_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00280-014-2526-5","volume":"74","author":"DM Keefe","year":"2014","unstructured":"Keefe DM, Elting LS, Nguyen HT, Grunberg SM, Aprile G, Bonaventura A, et al. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother Pharmacol. 2014;74:675\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","volume":"26","author":"SE Al-Batran","year":"2015","unstructured":"Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26:1244\u20138.","journal-title":"Ann Oncol"},{"key":"1112_CR24","doi-asserted-by":"crossref","unstructured":"Iwata H, Masuda N, Kim S-B, Inoue K, Rai Y, Fujita T, et al. Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: exploratory analyses from the phase III ExteNET trial. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res. 2018;78(4 Suppl):Abstract nr P1-13-11.","DOI":"10.1158\/1538-7445.SABCS17-P1-13-11"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-019-1112-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-019-1112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T19:11:53Z","timestamp":1582744313000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-019-1112-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1186\/s13058-019-1112-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by institutional review boards\/independent ethics committees at each site, and all patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM has performed a consulting or advisory role for Puma Biotechnology (ExteNET Data and Safety Monitoring Board). JdP has stock or other ownership in Novobiotics and Creatics, has received honoraria from Braintree Laboratories and Takeda, performed a consulting or advisory role for Braintree Laboratories and speakers\u2019 bureaus for Takeda and AstraZeneca, and is a member of the ExteNET Data and Safety Monitoring Board. KS has performed a consulting or advisory role for Puma Biotechnology (ExteNET Data and Safety Monitoring Board). YY is a former employee of Puma Biotechnology and owns stock in Puma Biotechnology and Amgen. MJ has received honoraria from Foundation Medicine; performed consulting or advisory roles for Novartis; Genentech, Lilly, Bristol-Myers Squibb, and Pfizer; received research funding from Genentech, Ariad, Clovis Oncology, and AbbVie, travel and accommodation expenses from Novartis, Genentech, Lilly, Ariad, Pfizer, and Bristol-Myers Squibb; and is a member of the ExteNET Data and Safety Monitoring Board for Puma Biotechnology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"32"}}